Abstract PARP inhibitors have revolutionized the management of ovarian cancer and are being licenced for other cancer indications. The clinical trials prompting licencing decisions in ovarian cancer were dominated by white participants or participant ethnicity was not documented. To compensate for this, replicative studies like L-MOCA can be run in specific ethnic groups. In future, strategies such as mandatory collection and publication of race and ethnicity data are essential alongside concerted efforts to widen the inclusivity of trial recruitment.
Clinical cancer research
American Association for Cancer Research (AACR)